The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance ...

The FDA has granted traditional approval to Rubraca (rucaparib) for metastatic castration-resistant prostate cancer.

A team of cancer biologists led by Princeton’s Yibin Kang has resolved a confounding paradox about retinoids and cancer cells ...

Artificial intelligence is making its way into every aspect of life, including cancer prevention. New technology at MUSC is ...

Recent advances in cancer biology have revealed that refractory malignancies, such as castration-resistant prostate cancer, pancreatic ductal ...